Cancer Biopsy Market Size To Reach $51.61 Billion By 2030

Cancer Biopsy Market Growth & Trends

The global cancer biopsy market size is estimated to reach USD 51.61 billion by 2030, and is projected to expand at a CAGR of 8.04%, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand – EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

 Request a free sample copy or view report summary: Cancer Biopsy Market Report

Cancer Biopsy Market Report Highlights

• In 2022, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies

• Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments

• In terms of application, breast cancer dominated the global market in 2022 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis

• North America held the largest revenue share in 2022 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity

• Some of the key market participants are QIAGEN, ANGLE plc, Myriad Genetics, Danaher, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, and BIOCEPT, INC. among others

Cancer Biopsy Market Segmentation

Grand View Research has segmented the global cancer biopsy market based on product, type, application, and region:

Cancer Biopsy Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Kits and Consumables

• Services

Cancer Biopsy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Tissue Biopsies

  • Needle Biopsies

    • Fine Needle Aspiration (FNA)

    • Core Needle Biopsy (CNB)

  • Surgical Biopsies

• Liquid Biopsies

• Others

Cancer Biopsy Application Outlook (Revenue, USD Million, 2018 - 2030)

• Breast Cancer

• Colorectal Cancer

• Cervical Cancers

• Lung Cancers

• Prostate Cancers

• Skin Cancers

• Blood Cancers

• Kidney Cancers

• Liver Cancers

• Pancreatic Cancers

• Ovarian Cancers

• Others

Cancer Biopsy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Cancer Biopsy Market

• Qiagen N.V.

• Illumina, Inc.

• ANGLE Plc

• BD (Becton, Dickinson and Company)

• Myriad Genetics

• Hologic, Inc.

• Biocept, Inc.

• Thermo Fisher Scientific, Inc.

• Danaher

• F. Hoffmann-La Roche Ltd.

• Lucence Diagnostics Pte. Ltd.

• GRAIL, Inc.

• Guardant Health

• Exact Sciences Corporation

• Freenome Holdings, Inc.

• Biodesix (Integrated Diagnostics)

• Oncimmune

• Epigenomics AG

• HelioHealth (Laboratory for Advanced Medicine)

• Genesystems, Inc. (Genesys Biolabs)

• Chronix Biomedical, Inc.

• Personal Genome Diagnostics Inc.

• Natera, Inc.

• Personalis Inc.